Latest Posts

Strong call for transparency on medicine prices, cost of R&D at WHO Fair Pricing...

“Medical innovation has little social value if most people cannot access its benefits…. this is a global human rights issue,” said Mariângela Simão, Assistant...

WHO Fair Pricing Forum: Watching for Drug Industry Accountability

by Katrina Perehudoff and Jennifer Sellin Expensive medicines are a ubiquitous challenge from which no government is immune. Excessive price hikes are an urgent human...

Humiragate: AbbVie’s desperate attempts to keep its monopoly

A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...

Faced with unreasonable medicines prices, the Netherlands introduces pharmacy exemption in patent law.

On 1 February 2019, article 53(3), second sentence of the Dutch Patent Act 1995 came into force introducing a patent exemption for the preparation...

Cystic Fibrosis Medicines Wars in Europe

Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...

Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda

On Thursday 24 January, the World Health Organization’s 144th Executive Board meeting will kick off in Geneva. One of the agenda items is access...

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).